Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder

References

• World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017.
   Google Scholar
• World Health Organization. WHO China Office Fact sheet. Beijing, China: World Health Organization; 2017.
   Google Scholar
• Hsieh CR, Qin X. Depression hurts, depression costs: the medical spending attributable to depression and depressive symptoms in China. Health Econ. 2018;27(3):525–544.
   PubMed Web of Science ®Google Scholar
• Zhang M. Major depressive disorder treatment guidelines in China. J Clin Psychiatry. 2010;71(Suppl E1):e06.
   PubMedGoogle Scholar
• Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851–855.
   PubMed Web of Science ®Google Scholar
• Kelly K, Posternak M, Alpert JE. Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues Clin Neurosci. 2008;10(4):409–418.
   PubMedGoogle Scholar
• Kikuchi T, Suzuki T, Uchida H, et al. Association between antidepressant side effects and functional impairment in patients with major depressive disorders. Psychiatry Res. 2013;210(1):127–133.
   PubMed Web of Science ®Google Scholar
• Demyttenaere K. Risk factors and predictors of compliance in depression. Eur Neuropsychopharmacol. 2003;13:69–75.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366.
   PubMed Web of Science ®Google Scholar
• Citrome L. Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2016;196:225–233.
   PubMed Web of Science ®Google Scholar
• Zimovetz EA, Wolowacz SE, Classi PM, et al. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review. Cost Eff Resour Alloc. 2012;10(1):1–1.
   PubMedGoogle Scholar
• Zimmerman M, McGlinchey JB, Posternak MA, et al. Remission in depressed outpatients: more than just symptom resolution? J Psychiatr Res. 2008;42(10):797–801.
   PubMed Web of Science ®Google Scholar
• IsHak WW, Bonifay W, Collison K, et al. The recovery index: a novel approach to measuring recovery and predicting remission in major depressive disorder. J Affect Disord. 2017;208:369–374.
   PubMed Web of Science ®Google Scholar
• IsHak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D). J Affect Disord. 2013;151(1):59–65.
   PubMed Web of Science ®Google Scholar
• Solomon DA, Leon AC, Endicott J, et al. Psychosocial impairment and recurrence of major depression. Compr Psychiatry. 2004;45(6):423–430.
   PubMed Web of Science ®Google Scholar
• Lam RW, McIntosh D, Wang J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and principles of care. Can J Psychiatry. 2016;61(9):510–523.
   PubMed Web of Science ®Google Scholar
• Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry. 2006;163(1):148–150.
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Donneau A-F, Albert A, et al. What is important in being cured from depression? Discordance between physicians and patients (1). J Affect Dis. 2015;174:390–396.
   PubMed Web of Science ®Google Scholar
• Thase ME, Mahableshwarkar AR, Dragheim M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016;26(6):979–993.
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242–252.
   PubMed Web of Science ®Google Scholar
• Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–223.
   PubMed Web of Science ®Google Scholar
• Thase ME, Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry. 1997;58(9):393–398.
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178(3):234–241.
   PubMed Web of Science ®Google Scholar
• Wang G, Gislum M, Filippov G, et al. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study. Curr Med Res Opin. 2015;31(4):785–794.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389.
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Supplement 3):89–95.
   PubMed Web of Science ®Google Scholar
• Llorca P-M, Lançon C, Brignone M, et al. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Curr Med Res Opin. 2014;30(12):2589–2606.
   PubMed Web of Science ®Google Scholar
• Thase ME, Danchenko N, Brignone M, et al. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. Eur Neuropsychopharmacol. 2017;27(8):773–781.
   PubMed Web of Science ®Google Scholar
• Florea I, Loft H, Danchenko N, et al. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav. 2017;7(3):e00622.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Harrison J, Loft H, et al. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016;19(10):pyw055.
   PubMed Web of Science ®Google Scholar
• Baune BT, Brignone M, Larsen KG. A network meta-analysis comparing effects of various antidepressant classes on the Digit Symbol Substitution Test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol. 2018;21(2):97–107.
   PubMed Web of Science ®Google Scholar
• Woo YS, Rosenblat JD, Kakar R, et al. Cognitive deficits as a mediator of poor occupational function in remitted major depressive disorder patients. Clin Psychopharmacol Neurosci. 2016;14(1):1–16.
   PubMed Web of Science ®Google Scholar
• Lam RW, Kennedy SH, McIntyre RS, et al. Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. Can J Psychiatry. 2014;59(12):649–654.
   PubMed Web of Science ®Google Scholar
• Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm. 2013;19(3):237–246.
   PubMed Web of Science ®Google Scholar
• Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders. J Affect Disord. 2018;227:787–794.
   PubMed Web of Science ®Google Scholar
• Cohen RM, Greenberg JM, IsHak WW. Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the individual burden of illness index for depression to measure treatment impact and recovery in MDD. JAMA Psychiatry. 2013;70(3):343–350.
   PubMed Web of Science ®Google Scholar
• Hawley CJ, Gale TM, Sivakumaran T. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002;72(2):177–184.
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Harnett-Sheehan K, Spann ME, et al. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. Int Clin Psychopharmacol. 2011;26(2):75–83.
   PubMed Web of Science ®Google Scholar
• Jha MK, Minhajuddin A, Greer TL, et al. Early improvement in work productivity predicts future clinical course in depressed outpatients: findings from the CO-MED trial. Am J Psychiatry. 2016;173(12):1196–1204.
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Simon GE, Kalsekar A, et al. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety. 2009;26(1):83–97.
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Nakagome K, Asami Y, et al. Restoring function in major depressive disorder: a systematic review. J Affect Disord. 2017;215:299–313.
   PubMed Web of Science ®Google Scholar
• Choi SE, Brignone M, Cho SJ, et al. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea. Expert Rev Pharmacoecon Outcomes Res. 2016;16(5):629–638.
   PubMed Web of Science ®Google Scholar
• Christensen MC, Munro V. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome. Curr Med Res Opin. 2018;34(4):593–600.
   PubMed Web of Science ®Google Scholar
• Soini E, Hallinen T, Brignone M, et al. Cost–utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):293–302.
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528.
   PubMed Web of Science ®Google Scholar
• McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733–744.
   PubMed Web of Science ®Google Scholar
• WHO Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2002.
   Google Scholar
• World Bank. 2017 [cited 2019 Apr 17]. Available from: https://data.worldbank.org/indicator/ny.gdp.pcap.cd
   Google Scholar
• Chen W, Wang S, Wang Q, et al. Direct medical costs of hospitalisations for mental disorders in Shanghai, China: a time series study. BMJ Open. 2017;7(10):e015652.
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(02):155–162.
   PubMed Web of Science ®Google Scholar
• Knoth RL, Bolge SC, Kim E, et al. Effect of inadequate response to treatment in patients with depression. Am J Manag Care. 2010;16(8):e188–e196.
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Kessler RC, Kelley D, et al. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety. 2010;27(1):78–89.
   PubMed Web of Science ®Google Scholar